Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease

JERUSALEM--(BUSINESS WIRE)--May 31, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news